What are the 2025 American Heart Association/American College of Cardiology (AHA/ACC) hypertension guidelines and the older JNC 6 hypertension guidelines?

2025 AHA/ACC Hypertension Guidelines

The 2025 AHA/ACC guidelines recommend initiating antihypertensive therapy at BP ≥130/80 mm Hg for adults with diabetes, chronic kidney disease, or PREVENT-estimated 10-year CVD risk ≥7.5%, with a preferred treatment target of <120/80 mm Hg and a recommended target of <130/80 mm Hg. 1

Key Definitions and Classification

Blood Pressure Categories (2025):

• Elevated BP: 120-139/80-89 mm Hg
• Stage 1 Hypertension: SBP 130-139 mm Hg and/or DBP 80-89 mm Hg
• Stage 2 Hypertension: SBP ≥140 mm Hg and/or DBP ≥90 mm Hg

Risk Assessment

The 2025 guidelines mandate use of the PREVENT (Predicting Risk of Cardiovascular Disease EVENTs) calculator to replace the previous pooled cohort equations for 10-year CVD risk estimation. 1 The 7.5% 10-year risk threshold determines treatment eligibility for adults without diabetes or CKD.

Treatment Initiation Thresholds

For Adults WITH Clinical CVD, Diabetes, or CKD:

• Initiate therapy at BP ≥130/80 mm Hg 1

For Adults WITHOUT Clinical CVD and Lower Risk (<7.5% 10-year PREVENT risk):

• SBP ≥130 mm Hg: Consider initiation after 3-6 months of lifestyle modification trial in adults ≥30 years 1
• DBP ≥80 mm Hg: Initiate therapy after 3-6 month lifestyle trial in adults ≥30 years, as DBP elevation independently increases CVD risk even when lifestyle changes fail 1

For Adults Age <30 Years:

• Data are limited; consider therapy after lifestyle modification attempts, but individualized assessment needed 1

Blood Pressure Targets

Preferred Target: <120/80 mm Hg (for most adults when tolerated) Recommended Target: <130/80 mm Hg (minimum goal for all treated adults) 1

This represents a significant shift toward more aggressive BP control compared to prior guidelines, with potential to prevent approximately 200,900 all-cause deaths and 162,600 cardiovascular deaths over 10 years if fully implemented. 2

First-Line Pharmacotherapy

Four drug classes are recommended as first-line agents based on high-quality RCT evidence showing CVD prevention compared to placebo: 1

1. Thiazide-type diuretics (including chlorthalidone and hydrochlorothiazide)
2. Long-acting dihydropyridine calcium channel blockers (CCBs)
3. ACE inhibitors (ACEi)
4. Angiotensin receptor blockers (ARBs)

For Stage 1 Hypertension (130-139/80-89 mm Hg):

• Initiate with a single first-line agent, then titrate and add sequential agents as needed 1

Important Safety Restriction:

• Simultaneous use of ACEi + ARB + renin inhibitor in any combination is contraindicated due to harm 1

Drug Selection Nuances

While all four first-line classes show similar overall CVD prevention, subtle differences exist in preventing specific events. A pragmatic RCT comparing HCTZ 25 mg to chlorthalidone 12.5 mg showed no difference in MACE overall, though adults with established ASCVD had greater benefit with chlorthalidone. 1 The choice between agents should consider compelling indications and side effect profiles.

Beta-blockers and alpha-blockers are not first-line agents due to less favorable stroke prevention and side effect profiles; reserve for compelling indications. 1

Population Impact

Under the 2025 guidelines, approximately 28% of US adults with hypertension (22.8 million) are eligible for pharmacotherapy, yet 43% of eligible adults remain untreated. 2 The guidelines particularly expand treatment eligibility among younger adults (age 30-60) and those with obesity. 3 Among currently treated adults, 59.8% do not meet the <130/80 target, and an additional 17.6% would benefit from intensification to reach the preferred <120/80 target. 3

---

Historical JNC 6 Guidelines (1997)

The JNC 6 (Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure) from 1997 represented the standard prior to modern evidence-based approaches:

JNC 6 Classification:

• Optimal: <120/<80 mm Hg
• Normal: <130/<85 mm Hg
• High-Normal: 130-139/85-89 mm Hg
• Stage 1 Hypertension: 140-159/90-99 mm Hg
• Stage 2 Hypertension: 160-179/100-109 mm Hg
• Stage 3 Hypertension: ≥180/≥110 mm Hg

JNC 6 Treatment Threshold:

• Initiate therapy at BP ≥140/90 mm Hg (significantly higher than 2025 guidelines)
• Target: <140/90 mm Hg for most adults
• Target: <130/85 mm Hg for adults with diabetes or renal disease

JNC 6 First-Line Agents:

• Diuretics and beta-blockers were preferred initial agents
• ACE inhibitors, calcium channel blockers, alpha-blockers, and alpha-beta blockers were alternatives

Key Evolution from JNC 6 to 2025: The treatment threshold has dropped from 140/90 to 130/80 mm Hg, targets have become more aggressive (<120/80 preferred vs. <140/90), risk-based treatment decisions now incorporate formal CVD risk calculators (PREVENT), and beta-blockers have been demoted from first-line status while ACEi/ARBs and CCBs have been elevated.